Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor and variant III targeted immunotherapy

1 Oct 2014

Abstract excerpt

Immunotherapeutic approaches to cancer have shown remarkable promise. A critical barrier to successfully executing such immune-mediated interventions is the selection of safe yet immunogenic targets. As patient deaths have occurred when tumor-associated antigens shared by normal tissue have been targeted by strong cellular immunotherapeutic platforms, route of delivery, target selection and the immune-mediated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25342601
DOI: 10.1093/neuonc/nou236

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor and variant III targeted immunotherapyPMID 25342601Read ↗

Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomasSemantic proximity Read ↗

The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.Semantic proximity Read ↗

The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant GliomasSemantic proximity Read ↗

Mutant epidermal growth factor receptors as targets for cancer therapy.Semantic proximity Read ↗

HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activationSemantic proximity Read ↗

High Affinity Chimeric Antigen Receptor with Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic IsoformsSemantic proximity Read ↗

Epidermal growth factor receptor targeting and challenges in glioblastomaSemantic proximity Read ↗

Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumorsSemantic proximity Read ↗

Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancerSemantic proximity Read ↗

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.Semantic proximity Read ↗

The epidermal growth factor receptor variant <scp>III</scp> (<scp>EGFR</scp>v<scp>III</scp>): where wild things are alteredSemantic proximity Read ↗

Targeting peptide antigens using a multiallelic MHC I-binding system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.